Evaluating the therapeutic potential of ADAR1 inhibition for triple-negative breast cancer

Triple-negative breast cancer (TNBC) is the deadliest form of breast cancer. Unlike other types of breast cancer that can be effectively treated by targeted therapies, no such targeted therapy exists for all TNBC patients. The ADAR1 enzyme carries out A-to-I editing of RNA to prevent sensing of endo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncogene
Main Authors: Kung, Che-Pei, Cottrell, Kyle A., Ryu, Sua, Bramel, Emily R., Kladney, Raleigh D., Bross, Emily A., Freeman, Eric C., Sabloak, Thwisha, Maggi, Leonard, Weber, Jason D.
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7796950/
https://ncbi.nlm.nih.gov/pubmed/33110236
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41388-020-01515-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados